#高警訊藥品

診斷或治療心室上心律不整
1. Paroxysmal supraventricular tachycardia
2. Pharmacologic stress testing
3. Acute vasodilator testing in pulmonary artery hypertension

Antiarrhythmic Drugs
Slows conduction time and interrupts the re-entry pathways through the AV node, restoring normal sinus rhythm

Metabolism: active metabolites (inosine and adenosine monophosphate)
Elimination Half Life: <10 s

1. Hypersensitivity to adenosine
2. Known or suspected bronchoconstrictive or bronchospastic lung disease (eg, asthma)
3. Second- or third-degree atrioventricular block (if no pacemaker is present)
4. Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (if no pacemaker is present)

B (FDA); B2 (AUS)

Infant risk cannot be ruled out.

Cardiovascular: Cardiac arrhythmia (transient and new arrhythmia after cardioversion; eg, atrial premature contractions, atrial fibrillation, premature ventricular contractions; 55%), chest pressure (and discomfort; 7% to 40%)
Central nervous system: Headache (2% to 18%), dizziness (?12%)
Dermatologic: Facial flushing (18% to 44%)
Gastrointestinal: Gastrointestinal distress (13%)
Neuromuscular & skeletal: Neck discomfort (includes throat, jaw; <1% to 15%)
Respiratory: Dyspnea (12% to 28%)

Advanced cardiac life support - Supraventricular tachycardia:
Initial 6 mg IV peripheral bolus over 1 to 2 seconds followed by 20 mL saline flush, increase to 12 mg every 1 to 2 minutes as needed for 2 doses; MAX 12 mg/dose
Paroxysmal supraventricular tachycardia:
Initial 6 mg IV peripheral bolus over 1 to 2 seconds, increase to 12 mg every 1 to 2 min as needed for 2 doses; MAX single dose 12 mg
Cardiac thallium-201 study; Adjunct:
140 mcg/kg/min IV for 6 min
Myocardial imaging, Technetium-99M:
140 mcg/kg/minute IV infusion for 6 minutes. Administer tracer injection over 10 to 20 seconds after 3 to 4 minutes of adenosine infusion (as early as 2 minutes after start of adenosine may be effective)
Stress echocardiography:
140 mcg/kg/min IV for 4 minutes, or less if angina was induced or in presence of perfusion or wall motion abnormalities

Advanced cardiac life support - Supraventricular tachycardia:
Initial 0.1 mg/kg IV or intraosseous followed by saline flush, MAX 6 mg/dose; may repeat at 0.2 mg/kg as needed; MAX 12 mg/dose
Paroxysmal supraventricular tachycardia:
Weight less than 50 kg: initial 0.05 to 0.1 mg/kg/dose IV as a rapid bolus (MAX 6 mg/dose); may repeat at increasing increments of 0.05 to 0.1 mg/kg/dose IV every 1 to 2 min as needed; MAX single dose of 0.3 mg/kg;
Weight at least 50 kg or above: initial 6 mg IV peripheral bolus over 1 to 2 seconds, increase to 12 mg every 1 to 2 min as needed for 2 doses; MAX single dose 12 mg

No dosage adjustment necessary.

No dosage adjustment necessary.

Room temperature